-
TREMFYA (guselkumab) is Johnson & Johnson's injectable IL-23 blocker, first approved in 2017 for plaque psoriasis and since expanded to psoriatic arthritis, ulcerative colitis (FDA supplemental approval Sept 26, 2025) and Crohn's disease (FDA supplemental approval May 28, 2026), per FDA BLA 761061 records. It is one of J&J's fastest-growing products: J&J's Q2 2026 earnings analysis cites TREMFYA sales up ~72.5% year over year, and royalty holder Royalty Pharma credits Tremfya among drivers of ~14% royalty-receipts growth in Q2 2026. Because the big regulatory binaries have already passed, TREMFYA is now a commercial-growth story inside a ~$600B mega-cap: bullish for the franchise, but with no single near-term event likely to move JNJ sharply (the 2017 approval itself moved the stock only ~+0.3% in a day per local records).
Explore drug → -
CARVYKTI (ciltacabtagene autoleucel / cilta-cel) is an approved, marketed CAR-T cell therapy for multiple myeloma, developed and co-commercialized by Johnson & Johnson's Janssen unit (JNJ) and Legend Biotech (LEGN), where it is essentially Legend's entire business. Net trade sales are growing ~50-62% year over year — about $657M in Q2 2026 and $1.9B for full-year 2025 — with durable efficacy (30-month OS >85% among CARTITUDE-4 responders) and expansion to 18 countries and 10,000+ patients treated. For JNJ it is a meaningful but non-binary growth driver inside a ~$101B guided revenue base; the bull/bear question for the stock is commercial momentum and competition, not a pending approval decision.
Explore drug → -
DARZALEX (daratumumab) is the standard-of-care backbone of multiple-myeloma therapy, sold by Johnson & Johnson's Janssen unit under a license from Genmab, which reports the product's worldwide net sales quarterly and takes royalties. The drug is approved in multiple myeloma indications (IV form since Nov 2015, subcutaneous FASPRO since May 2020, plus a 2026 label expansion for newly diagnosed patients), and it keeps growing: worldwide net sales were USD 4,207M in Q2 2026 (US $2,435M, rest-of-world $1,772M) after $3.964B in Q1 2026, and J&J's Q2 2026 earnings analysis named DARZALEX a key driver behind its raised FY2026 guidance. The bull case is a proven, growing, multi-indication franchise with no near-term binary risk; the bear case is competition (BMS' iberdomide combo PDUFA Aug 17, 2026 and CAR-T rivals), eventual biosimilar erosion, and the fact that for a ~$260/share mega-cap there is no single DARZALEX catalyst to trade around.
Explore drug →
Revita is Fractyl Health's (Nasdaq: GUTS) lead asset — a one-time, endoscopically-delivered duodenal mucosal resurfacing device for weight maintenance in people with obesity who discontinue GLP-1 therapies. The FDA granted Breakthrough Device designation on May 12, 2026, and the stock jumped ~23% in one day. Interim one-year data (July 2026) showed Revita retained 81% of prior GLP-1 weight loss vs 48% for sham, but the real test is the REMAIN-1 Pivotal Cohort (N=315) topline 6-month readout expected early Q4 2026, with a potential FDA De Novo submission targeted for late Q4 2026.
ABP-450 is AEON Biopharma's (NYSE American: AEON) only disclosed drug candidate — a botulinum toxin type A developed as a biosimilar to BOTOX for full-label US therapeutic use. The program is early-stage on the regulatory pathway (FDA Type 2a meeting done, Type 2b planned 2H26, no BLA filed, Phase 3 not started), while the company is a distressed, pre-revenue microcap: FY2025 net loss of $39.2M, a ~$55M stockholders' deficit, a NYSE American delisting notice, and a massively dilutive July 2026 financing (17.85M shares + 24.84M pre-funded + 85.38M milestone warrants at ~$0.32/unit). Net read: bearish — no near-term binary catalyst, heavy dilution and listing risk dominate the story.
TPST-4003 is Tempest Therapeutics' (Nasdaq: TPST) lead in vivo CAR-T candidate — a CD7-targeted mRNA/lipid-nanoparticle therapy for autoimmune diseases, initially myasthenia gravis and multiple sclerosis. It is the centerpiece of a company that pivoted from small molecules to CAR-T via a February 2026 all-stock acquisition of Factor Bioscience assets, and it has a July 2026 development collaboration with China's Senlang Biotechnology. The drug has no human data yet: a ~10-patient investigator-initiated trial is expected to begin dosing in Q4 2026 with initial data in H1 2027. The setup is a high-risk binary: the stock (~$1.13, ~$19M market cap) is entirely driven by this early-stage program, but the company had only ~$0.8M of cash at Q2 2026, faces a Nasdaq delisting deficiency notice, and carries significant dilution overhang — so financing risk likely precedes any data catalyst.
Vebreltinib (APL-101/PLB1001) is Apollomics Inc.'s (Nasdaq: APLM) lead drug, an oral c-MET inhibitor for non-small cell lung cancer, currently in Phase 2 with no U.S. IND yet (planned 2027). The company's finances are the story: $3.3M cash at end-2025, a going-concern warning in its 20-F, a $2M CEO bridge note convertible at an 80% discount, an active F-3 shelf, and a June 2026 license termination after partner LaunXP failed to pay $3.8M (rights to vebreltinib were regained). The stock avoided delisting (Nasdaq MVLS compliance restored July 2026) and trades around $23.40 on a tiny ~2.2M-share float with a 52-week range of $3.66–$42.12.
YB-101 is the lead and essentially only clinical asset of Yarrow Bioscience (Nasdaq: YARW), formed when private Yarrow reverse-merged into VYNE Therapeutics in late July 2026 (VYNE shareholders ended up with ~3% of the combined company, which raised ~$200M and has runway into 2028). It is a potential first-in-class anti-TSHR antibody with FDA Fast Track designation for Graves' disease; a Phase 2a/2b trial began dosing at the merger close, with proof-of-concept data guided for 2H 2027. The bull case rests on a differentiated mechanism, an encouraging early Phase 1 signal and a long cash runway; the bear case is that this is a single-asset, no-revenue company whose one meaningful binary is roughly a year away, facing competition from anti-FcRn/IgG-degrading biologics in the same space.
WTX-124 is a pipeline program at Werewolf Therapeutics (Nasdaq: HOWL), a ~$22M micro-cap that confirmed in its July 31, 2026 Q2 update that it is still developing the drug while reviewing strategic alternatives with Piper Sandler. The company just sold its JZP898 program to Jazz Pharmaceuticals for $21.0M (the entire Q2 revenue), leaving ~$22.0M cash and a runway guided into Q2 2027, with persistent selling by insider/VC holders (MPM, RA Capital, UBS Oncology) and no scheduled WTX-124 clinical catalyst in SecBot's data.
Zumilokibart (APG777) is Apogee Therapeutics' lead asset — a half-life-extended anti-IL-13 antibody in development for atopic dermatitis, asthma, and eosinophilic esophagitis — and the reason AbbVie agreed on June 22, 2026 to buy Apogee for $135.11 per share in cash (~$10.9 billion), AbbVie's largest deal in more than half a decade. Phase 2 APEX data were positive (Part B: 65.9% EASI-75 vs. 23.4% placebo, p<0.001; Part A: durable 52-week maintenance on every-3/6-month dosing), supporting Phase 3 initiation in 2H 2026 and a potential 2029 launch, with up to $1.3B in Blackstone Life Sciences non-dilutive financing already secured. The developer stock (APGE) now trades ~0.7% below the cash offer, so the remaining near-term binary is the deal close (expected Q3 2026), not a drug readout; for AbbVie, zumilokibart is a 2030s "mega-blockbuster" bet that carries ~$0.14 of 2026 EPS dilution.
Elritercept is Keros Therapeutics' lead hematology drug, licensed globally to Takeda under a deal effective January 2025 that brought a $200M upfront payment and eligibility for $1.1B+ in milestones plus tiered royalties. The pivotal Phase 3 ELRiSE MDS trial (vs epoetin alfa in low-risk MDS) dosed its first patient in July 2026 — triggering a $20M milestone, 25% of which Keros plans to distribute to stockholders — and Takeda is planning a Phase 3 in myelofibrosis. KROS trades near its 52-week low (~$10.07 vs $22.55 high) with a mean analyst price target of ~$21.83, but remains pre-revenue with no near-term binary: Phase 3 readouts are years out.
LT-100 is the lead development program of Lōkahi Therapeutics, the San Diego biopharma that took control of Glucotrack, Inc. (Nasdaq: GCTK) via a reverse merger closed July 14, 2026 — Lōkahi holders received ~90% of post-merger equity, cutting legacy Glucotrack shareholders to roughly 10%. LT-100 is still pre-clinical: an FDA Type C meeting (May 2026) and a minipig study support a planned first clinical evaluation as early as Q4 2026 with an initial readout guided to H1 2027, but there is no human efficacy data, no registered trial, and no dated binary. The stock context is heavily bearish — ~30.95% of estimated shares outstanding held short (settlement 7/15/26), Reg SHO threshold-list entry since 7/20/26, a ~56% short-volume day on 7/30/26, a Nasdaq volatility pause, and pending delisting risk.
Revlimid (lenalidomide) is the Celgene blockbuster that became a Bristol Myers Squibb product in the 2019 acquisition; first approved in the US in 2005, it peaked near $12.8B in 2021. US exclusivity is gone: the first generic arrived March 2022 and the last volume caps on generic supply ended Jan 31, 2026, unleashing full price competition (Accord launched Feb 2026). BMS's Q2 2026 earnings showed Revlimid down ~49% YoY — but the company beat estimates and raised guidance on its Growth Portfolio, so Revlimid is now a melting legacy asset rather than a thesis-driver. No regulatory or clinical catalyst for Revlimid is pending.
Nuzefatide pevedotin is Bicycle Therapeutics plc's (BCYC, Nasdaq) EphA2-targeted Bicycle Toxin Conjugate and one of two lead programs (the other is zelenectide pevedotin, a separate molecule in the Duravelo trials). April 2026 Phase 1/2 data showed a 40% confirmed response rate with nivolumab in EphA2+ metastatic urothelial cancer, and a Phase 2 pancreatic cancer trial is now enrolling. BCYC is a pre-revenue clinical-stage company: Q2 2026 net loss was $50.3M (-$0.72/sh), cash was $510.1M with runway into 2030 after a March 2026 restructuring (30% workforce cut, Duravelo-3/4 deprioritized, Genentech/Novartis collaborations terminated). The stock is near its 52-week low with no FDA/PDUFA catalysts on record and no dated near-term pivotal readout, so the near-term share-price driver for THIS drug is modest — but it carries the weight of a major program at a ~$270M-market-cap company.
-
ORPATHYS (savolitinib), a MET-targeting cancer pill developed by HUTCHMED (HCM) with partner AstraZeneca, is already a commercial product in China: it holds three NMPA approvals (MET-mutated lung cancer; and as of July 2026, MET-amplified gastric cancer) and is on China's National Reimbursement Drug List. The near-term investor question is not the drug's validity but its next-stage growth: HUTCHMED's H1 2026 results guide SAFFRON (global) and SANOVO (China) Phase 3 topline readouts to H2 2026, which would unlock ex-China filings. Analyst consensus is strongly positive (23 buy/strong-buy vs 3 hold, mean target $21.77 vs $11.13), but the stock sits near its 52-week low and the pending pivotal readout is a genuine two-sided binary.
Explore drug → -
ELUNATE is HUTCHMED (HCM)'s China brand name for fruquintinib (development code HMPL-013), an oral VEGFR-inhibitor already marketed in China and, under the brand FRUZAQLA, in 41 countries ex-US. China's NMPA approved it in combination with sintilimab for 2nd-line advanced/metastatic renal cell carcinoma in May 2026 (FRUSICA-2: 63% risk reduction, mPFS 22.2 vs 6.9 months), and H1 2026 results show ELUNATE in-market sales up 41% to $60.8M — the company's largest marketed China product. It is a mature commercial asset with no scheduled binary catalyst of its own in the next 12 months; the next company-level catalysts are for other drugs.
Explore drug →
-
Venglustat (GZ402671) is Sanofi's oral glucosylceramide-synthase inhibitor in development for rare sphingolipid storage diseases. The headline catalyst is an NDA under FDA priority review for Gaucher disease type 3 — the Phase 3 LEAP2MONO study met both primary endpoints and three of four key secondary endpoints, and approval would make it the first US treatment addressing the neurological manifestations of GD3, with a target action date of November 25, 2026 (per Sanofi's June 8, 2026 6-K). The program has had setbacks — the Phase 3 GM2 (Tay-Sachs/Sandhoff) trial was terminated — and a Phase 3 Fabry trial (n=104) passed its estimated primary completion in May 2026 with no results posted in local data. Because venglustat targets tiny patient populations inside a ~$110B mega-cap, the PDUFA is a genuine dated binary but a small share-price driver for SNY.
Explore drug → -
Redemplo (generic plozasiran, codes ARO-APOC3/VSA001/SAR449124) is Arrowhead Pharmaceuticals' (ARWR, Nasdaq) lead siRNA drug; the FDA approved it in November 2025 for familial chylomicronemia syndrome (FCS), an ultra-rare genetic disorder of extremely high triglycerides, and ARWR jumped ~30% (stored 1-day move: $44.26 → $57.71) around the approval-related catalyst dated Nov 25, 2025. The far larger prize is severe hypertriglyceridemia (SHTG): two Phase 3 trials are expected to read out around June–Sept 2026, and FDA granted Breakthrough Therapy designation in Feb 2026, with a positive EMA EPAR opinion in April 2026. The SNY/Sanofi hint appears to trace to the Sanofi-style code SAR449124 in a China FCS Phase 3 study sponsored by Visirna Therapeutics — Sanofi is not the US developer.
Explore drug →
Cemdisiran is Regeneron's investigational siRNA therapy targeting complement C5 for generalized myasthenia gravis (gMG). It posted positive Phase 3 NIMBLE results (primary and key secondary endpoints met) and its NDA was accepted by the FDA under Priority Review with a target action date of November 2026; the EMA decision is expected in H2 2027, and it could be the first siRNA approved for gMG with quarterly subcutaneous dosing. SecBot's catalyst records also tag Alnylam (ALNY), the RNAi platform's originator, alongside REGN.
CagriSema (cagrilintide + semaglutide) is Novo Nordisk's (NVO) flagship next-generation obesity/type-2-diabetes combination, and its Phase 3 program is essentially complete per locally ingested ClinicalTrials.gov records — including head-to-head trials versus Lilly's tirzepatide — but no efficacy results have been posted yet, and there is no FDA approval or PDUFA record in the local FDA data. That makes the imminent Phase 3 readouts the pivotal near-term binary for the stock. Rating is mixed: strong strategic importance and low short crowding versus unconfirmed efficacy, fierce competition, and a weak analyst/valuation backdrop (NVO consensus is Hold-heavy; mean price target $47.79, implied upside -1.2%; six downgrades in the past year).
z-basivarsen is Dyne Therapeutics' (Nasdaq: DYN) lead drug for myotonic dystrophy type 1 (DM1), an antisense-oligonucleotide therapy that targets the toxic RNA driving the disease. Dyne announced in June 2026 that the registrational expansion cohort of the Phase 1/2 ACHIEVE trial was fully enrolled (71 participants), with topline data guided for Q1 2027, a potential U.S. Accelerated-Approval BLA in Q3 2027, and a potential launch in H1 2028; a Phase 3 confirmatory trial (HARMONIA) is already running. The company has no approved products, so this readout is a defining binary, balanced against a fully-funded balance sheet (cash runway into Q2 2028), strong analyst consensus (mean target ~$39.5 vs ~$25 share price), but also meaningful competition (Avidity's del-desiran Phase 3 DM1 trial has an earlier estimated primary completion of Aug 2026), recent dilution, insider selling, and ~13% short interest.
AMT-162 (formerly Apic Bio's APB-102, licensed by uniQure in 2023) was a one-time, intrathecal AAVrh10 gene therapy for SOD1-ALS, an ultra-rare genetic form of ALS. It never got past a small Phase 1/2 trial (EPISOD1): after a positive first-cohort safety review (Jan 2025), enrollment was paused in 2025 following a dose-limiting toxicity, and uniQure officially discontinued development on May 5, 2026 after reviewing data from just five dosed patients. The program is now dead, and its already-small role in uniQure's value is zero; the stock (~$43.63 on 7/31/2026) is driven by the AMT-130 Huntington's program, with analysts still largely bullish (mean price target ~$65.5, strong-buy consensus) and cash of ~$586.6M funding operations into 2H 2029.
AVT16 is Alvotech's proposed interchangeable biosimilar to Takeda's Entyvio (vedolizumab), a blockbuster IV biologic for ulcerative colitis and Crohn's disease. Its aBLA was the first vedolizumab biosimilar accepted for FDA review (June 8, 2026), with a decision expected in Q1 2027. The reference product generated ~$6B in Takeda's FY2024/25, and AVT16 would be marketed by Teva in the US. A May 2026 FDA manufacturing inspection closed with a favorable VAI classification in July 2026, clearing a key regulatory overhang. However, Fresenius Kabi/Polpharma's competing vedolizumab biosimilar (PB016) had its BLA accepted just two months later (July 31, 2026), narrowing the first-mover window, and Alvotech's history of CRLs and recent dilutive equity raises add risk.
-
HCW11-018b is the lead T-cell engager of HCW Biologics (Nasdaq: HCWB), a micro-cap clinical-stage biopharma in Miramar, FL, developing "fusion immunotherapeutics" for cancer, autoimmune disease and senescence-related conditions. It is a preclinical, IND-enabling asset: an April 27, 2026 announcement reported mechanism-of-action data validating tissue factor as a target and showing potent antigen-specific anti-pancreatic-cancer activity in animal models, but no clinical trial exists yet and no IND/Phase 1 date is scheduled. The drug sits inside a company in acute financial stress — going-concern doubt disclosed in Q1 2026, a 1-for-6 reverse split (June 30, 2026), a Nasdaq delisting fight, and two dilutive private placements in 2026 (~$4.0M in May at $1.405/unit; $1.6M in July) — so the science is intriguing but the investment setup is highly speculative.
Explore drug → -
HCW9302 is HCW Biologics' (HCWB, Nasdaq) IL-2-based fusion immunotherapeutic in Phase 1 for alopecia areata, an autoimmune hair-loss disease; June 2026 preliminary data showed 3/3 patients in the 3 µg/kg cohort hit ≥25% SALT reduction with a clean safety profile, and the company targets RP2D selection by year-end 2026. Bullish on the early signal and insider buying, but the stock is a micro-cap in distress: a going-concern disclosure, a Nasdaq delisting fight (1-for-6 reverse split June 30, 2026), and two dilutive 2026 private placements mean financing risk, not just trial risk, dominates the investment case.
Explore drug →
Simufilam is the sole pipeline asset of Filana Therapeutics (FLNA), a micro-cap biotech that rebranded from Cassava Sciences in March 2026 after abandoning Alzheimer's and pivoting to TSC-related epilepsy (~45,000 U.S. patients). The drug is promising only at the preclinical stage (mouse-model data in Epilepsia), and its clinical path is blocked: FDA placed a full clinical hold on the IND in December 2025, still unresolved as of the July 29, 2026 Q2 report. Financially, the company has no revenue, an $82.7M cash balance burning ~$12.7M per half-year, and a $31.25M litigation settlement already paid into escrow. Net investor read is bearish near-term: an undated regulatory overhang on the only asset, near the 52-week low, with bearish positioning signals — though the stock retains speculative optionality if the hold is ever lifted.
-
Niktimvo (axatilimab-csfr) is an FDA-approved first-in-class CSF-1R-blocking antibody for chronic graft-versus-host disease (cGVHD) after ≥2 prior lines of therapy, co-developed and co-commercialized by Syndax Pharmaceuticals (SNDX) and Incyte (INCY). Approved in August 2024, it generated $151.6 million in net revenue to Incyte in its first full year (2025), with Syndax recording $42.4M in collaboration revenue (50% of net commercial profit). The drug already annualizes at roughly $220M as of Q1 2026. Beyond cGVHD, a Phase 2 IPF (idiopathic pulmonary fibrosis) trial (MAXPIRe) is reading out in Q4 2026 — a potential multi-billion-dollar market if positive. Analyst consensus on SNDX is Strong Buy (19 Buy, 1 Hold) with a mean price target of $39, implying ~76% upside from ~$22.
Explore drug → -
Revuforj (revumenib) is Syndax Pharmaceuticals' first-in-class oral menin inhibitor, FDA-approved for two types of relapsed/refractory acute leukemia: KMT2A-rearranged (Nov 2024) and NPM1-mutated AML (Oct 2025). It generated $125M in net revenue in its first full year (FY2025) and $48.9M in Q1 2026 (+144% YoY), with the company's two approved drugs (Revuforj + Niktimvo) annualizing at ~$200M combined. However, Kura Oncology's Komzifti (ziftomenib) won FDA approval for the same NPM1-mutated AML indication in Nov 2025, creating direct competition. Syndax carries a consensus Strong Buy rating with a mean 12-month price target of $39 (~76% upside) and a $352M cash position. The stock has seen insider option exercises and sales (CEO via 10b5-1 plan). The defining binary events are past; the bull case rests on commercial execution, market share retention, and pipeline expansion.
Explore drug →
-
Auryon is a FDA-cleared, commercially launched peripheral atherectomy laser system from AngioDynamics (NASDAQ: ANGO), acquired via the 2019 Eximo Medical purchase for $46M. It uses a proprietary 355-nm solid-state laser to treat peripheral artery disease (PAD) by vaporizing plaque in leg arteries. Auryon has become AngioDynamics' flagship growth product, delivering 20 consecutive quarters of double-digit sales growth and driving the company's Med Tech segment transformation. In Q4 FY2026 (reported July 14, 2026), Auryon generated $17.8M in sales (+14.4% YoY) as part of a $41.8M Med Tech segment. The AMBITION BTK randomized trial for below-the-knee critical limb ischemia began enrollment in July 2025. The company faces stiff competition from Medtronic, Philips, Boston Scientific, and Abbott in the ~$1.1B atherectomy device market. Analyst consensus is heavily bullish (9 buy/strong-buy, 1 hold) with a mean price target of $18, implying ~44% upside.
Explore drug → -
AlphaVac is AngioDynamics' mechanical thrombectomy device for removing blood clots from large veins, including pulmonary embolism (PE). Already FDA-cleared (initial 2021, PE-specific April 2024, expanded VTE Nov 2025) and CE-marked in Europe (May 2024). The APEX-AV trial published in JSCAI (Jan 2025) showed 35.5% clot burden reduction, and the RECOVER-AV long-term outcomes study began enrollment in June 2025. It competes in a ~$1.9B thrombectomy device market growing ~7% CAGR, against Inari Medical's FlowTriever (acquired by Stryker for $4.9B in Dec 2025) and Penumbra's Indigo. AlphaVac is one of several growth drivers in AngioDynamics' Med Tech segment (FY2026: $150M, +18.4% YoY) but is not the company's primary near-term catalyst — that distinction belongs to the NanoKnife oncology platform.
Explore drug →